- Home
- OOMA vs IMAB Comparison
OOMA vs IMAB Comparison
Compare OOMA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OOMA
- IMAB
- Stock Information
- Founded
- OOMA 2003
- IMAB 2014
- Country
- OOMA United States
- IMAB United States
- Employees
- OOMA N/A
- IMAB N/A
- Industry
- OOMA EDP Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OOMA Technology
- IMAB Health Care
- Exchange
- OOMA Nasdaq
- IMAB Nasdaq
- Market Cap
- OOMA 345.3M
- IMAB 384.6M
- IPO Year
- OOMA 2015
- IMAB 2020
- Fundamental
- Price
- OOMA $13.09
- IMAB $3.65
- Analyst Decision
- OOMA Strong Buy
- IMAB Strong Buy
- Analyst Count
- OOMA 5
- IMAB 5
- Target Price
- OOMA $17.63
- IMAB $6.80
- AVG Volume (30 Days)
- OOMA 215.3K
- IMAB 1.7M
- Earning Date
- OOMA 08-26-2025
- IMAB 11-02-2025
- Dividend Yield
- OOMA N/A
- IMAB N/A
- EPS Growth
- OOMA N/A
- IMAB N/A
- EPS
- OOMA N/A
- IMAB N/A
- Revenue
- OOMA $261,617,000.00
- IMAB N/A
- Revenue This Year
- OOMA $6.45
- IMAB N/A
- Revenue Next Year
- OOMA $5.70
- IMAB N/A
- P/E Ratio
- OOMA N/A
- IMAB N/A
- Revenue Growth
- OOMA 5.42
- IMAB N/A
- 52 Week Low
- OOMA $10.88
- IMAB $0.60
- 52 Week High
- OOMA $17.00
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- OOMA 60.70
- IMAB 44.80
- Support Level
- OOMA $12.43
- IMAB $3.20
- Resistance Level
- OOMA $13.28
- IMAB $4.64
- Average True Range (ATR)
- OOMA 0.36
- IMAB 0.38
- MACD
- OOMA 0.01
- IMAB -0.16
- Stochastic Oscillator
- OOMA 77.70
- IMAB 30.20
About OOMA Ooma Inc.
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).